SEATTLE--(BUSINESS WIRE)--Acucela Inc., a clinical-stage biotechnology company focused on developing new treatments for blinding eye diseases, today announced that clinical and preclinical data will be presented during poster sessions at The Association for Research in Vision and Ophthalmology (ARVO) 2012 Annual Meeting being held May 6-10, 2012, in Fort Lauderdale, Fl. Among them, data from the Company’s Phase 2a trial evaluating ACU-4429 in patients with the advanced form of dry age-related macular degeneration (dry AMD/geographic atrophy) will be presented by John Chandler, M.D., Vice President of Clinical Affairs, Acucela, and David G. Birch, Ph.D., Chief Scientific and Executive Officer, Retina Foundation of the Southwest (poster 2044/D1062).
